Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

We’ve always assumed <keyword id="19900302" type="General" weightage="20" keywordseo="ageing" source="keywords">ageing</keyword> is a gradual decline, a slow march toward senescence. Wrinkles deepen, joints stiffen, and energy wanes — all part of the inevitable ageing process. But a groundbreaking new study is challenging this long-held belief. Instead of a steady slope, researchers have discovered that ageing happens in bursts. There are specific periods in our lives when the body undergoes rapid and significant changes. These acceleration points, identified at around age 44 and again at 60, could explain why certain health issues tend to spike at particular ages. Imagine your life as a journey with smooth stretches interspersed with steep inclines. The study suggests that these inclines are when the most dramatic changes occur. Your <keyword id="22839896" type="General" weightage="20" keywordseo="body-chemistry" source="keywords">body chemistry</keyword> shifts dramatically, from how it metabolises food to the way your immune system functions. <div type="Article" hostid="261" msid="112159814" title="Want to age slower? You can start by cutting all that sugar out of your diet!" mstype="2" mssubtype="0"></div><h2>The ageing accelerators </h2>The first of these critical age periods hits around 44. This is when many people start to notice more pronounced changes. Wrinkles deepen, energy levels may dip, and the first signs of joint stiffness might appear. But it's not just about outward appearances. Behind the scenes, the body is undergoing a significant molecular overhaul. The second wave of <keyword id="22839894" type="General" weightage="20" keywordseo="accelerated-ageing" source="keywords">accelerated ageing</keyword> begins in the early 60s. This is when the risk of <keyword id="19946459" type="General" weightage="20" keywordseo="chronic-diseases" source="keywords">chronic diseases</keyword> like heart disease and Alzheimer's tends to climb sharply. The body's systems, once finely tuned, start to show signs of wear and tear. Understanding these <keyword id="22839895" type="General" weightage="20" keywordseo="age-bursts" source="keywords">age bursts</keyword> is crucial. By pinpointing these periods of rapid change, scientists hope to develop targeted interventions. Imagine being able to bolster your body's defences during these critical times, much like a gardener fertilising plants during peak growth periods. <div type="Article" hostid="261" msid="112503037" title="A doctor who says he&amp;#39;s reversed his age by 20 years eats these 7 foods every week to boost his longevity" mstype="2" mssubtype="0"></div><h2>A new frontier in <keyword id="20585767" type="General" weightage="20" keywordseo="anti-aging" source="keywords">anti-aging</keyword> </h2>The implications of this research are profound. If we can pinpoint when our bodies are most vulnerable to age-related changes, we can develop strategies to mitigate their impact. Imagine tailored exercise routines designed to combat the muscle loss that accelerates in our mid-40s, or nutritional plans optimised to support the body's shifting metabolism in our early 60s. This knowledge could also revolutionise drug development. By understanding the specific <keyword id="22102247" type="General" weightage="20" keywordseo="molecular-changes" source="keywords">molecular changes</keyword> that occur during these age bursts, <keyword id="20068099" type="General" weightage="20" keywordseo="pharmaceutical-companies" source="keywords">pharmaceutical companies</keyword> might be able to create targeted therapies to slow down or even reverse some of the ageing process. While we're still in the early stages of this research, the possibilities are incredibly exciting. As we continue to unravel the mysteries of ageing, we move closer to a future where we can not only live longer but live healthier, more vibrant lives. <div type="Article" hostid="261" msid="112405984" title="Anti-aging enthusiasts are getting $16,500 injections to make their knees young again" mstype="2" mssubtype="0"></div>

Human ageing dramatically speeds up around ages 44 and 60, claims study

<keyword id="15160768" type="General" weightage="20" keywordseo="presvu" source="Orion">PresVu</keyword> eye drops, developed by <keyword id="20007796" type="General" weightage="20" keywordseo="entod-pharmaceuticals" source="keywords">Entod Pharmaceuticals</keyword>, were launched with considerable media attention earlier this month as a novel solution for <keyword id="23035383" type="General" weightage="20" keywordseo="presbyopia" source="keywords">presbyopia</keyword>. Presbyopia is a condition where individuals aged 40 and above experience difficulty focusing on nearby objects, often requiring reading glasses. PresVu claimed to reduce or eliminate the need for these glasses, offering an alternative through its active ingredient, 1.25% Pilocarpine, which temporarily contracts the pupil, improving near vision. Entod Pharmaceuticals earlier announced that the product had approval from the <keyword id="20047866" type="General" weightage="20" keywordseo="drug-controller-general-of-india" source="keywords">Drug Controller General of India</keyword> (<keyword id="20046022" type="General" weightage="20" keywordseo="dcgi" source="keywords">DCGI</keyword>). These announcements created substantial buzz, as the treatment promised a non-invasive solution to a common problem affecting millions of people. <h2>Regulatory backlash</h2>The situation escalated when the Drug Controller General of India suspended the marketing and distribution licence of PresVu eye drops. The suspension was issued due to unauthorised promotional campaigns by Entod, which made unverified claims about the drug's capabilities. The company had reportedly promoted PresVu not as a prescription drug, but as an over-the-counter (OTC) solution that could potentially replace reading glasses — a claim that regulators found highly misleading. The DCGI expressed concerns that such promotions could lead to misuse, with patients potentially self-administering the product without medical guidance, raising significant safety concerns. Furthermore, the regulatory body pointed out that while the product had been approved as a prescription drug, the marketing blitz implied it was a quick-fix solution available to anyone, which it was not. <h2>Entod Pharmaceuticals responds</h2>Entod Pharmaceuticals quickly defended itself against these allegations, maintaining that their marketing campaign was based on the information cleared by the DCGI. According to Entod, the promotion highlighted only the approved uses of the <keyword id="4537914" type="General" weightage="20" keywordseo="eye-drop" source="Orion">eye drop</keyword>, and any misconceptions arose from how the media and public interpreted the information. The company asserted that it would challenge the suspension in court, emphasising that other pharmaceutical companies frequently follow similar marketing practices without facing such scrutiny. In a statement, Entod’s CEO, <keyword id="21011592" type="General" weightage="20" keywordseo="nikkhil-k-masurkar" source="keywords">Nikkhil K Masurkar</keyword>, clarified that the company had conducted phase 3 clinical trials in India to ensure the product’s safety and efficacy. <div type="Article" hostid="261" msid="113251803" title="The next big market for weight-loss drugs: children" mstype="2" mssubtype="0"></div>“Our approval by DCGI was based on a valid controlled clinical trial in 234 patients which was successful in showing efficacy and safety of these eye drops in patients of Presbyopia, who used these drops without eyeglasses and could read additional lines on Snellen's chart which is yardstick of near vision impairment,” Masurkar commented in a statement. He insisted that the product’s promotional activities had followed standard protocols and blamed the viral nature of media reports for blowing the issue out of proportion. Despite these defences, the product remained suspended pending further investigations. "Such eye drops with the same active ingredient and same concentration have been approved by the US <keyword id="19918726" type="General" weightage="20" keywordseo="fda" source="keywords">FDA</keyword> and marketed in the US for the last three years without any serious complications. FDA didn’t take any action on the companies marketing the same in the USA,” Masurkar further elaborated. <h2>Public and expert reactions</h2>The controversy garnered widespread attention, particularly from medical professionals. The Liver Doc, a prominent liver specialist that takes to social media to debunk pseudoscientific claims, criticised the situation on X (former Twitter), warning about the dangers of exaggerated medical claims in advertising. The doctor’s tweet emphasised that blaming Indian media for blowing Entod’s claims out of proportion was “shameless”, noting that the media merely reported exactly what the company had themselves claimed earlier. <div type="twitter" handle="theliverdr" handlename="theliverdr" favoritecount="0" retweetcount="0" id="1833828866210849170"></div>As of September 12, 2024, the suspension of PresVu's marketing approval remains in place. Entod Pharmaceuticals is preparing to contest the decision in court, hoping to reinstate its flagship product in the Indian market. The regulatory investigation continues, with the DCGI seeking clarification on the exact nature of the promotions and whether they indeed violated ethical standards. <div type="Article" hostid="261" msid="113229771" title="China&amp;#39;s drug regulator clears mpox vaccine; to undergo clinical trial" mstype="2" mssubtype="0"></div>Despite Entod’s defence, the controversy has raised important questions about the marketing of prescription drugs in India, with regulators, the media, and the public closely watching how this case will evolve. The outcome could set a precedent for how pharmaceutical companies in India can market innovative treatments, particularly when dealing with sensitive areas like vision correction.

PresVu eye drops: Why has a pharma company fallen in controversy for claiming to cure near-sightedness?

India is on the brink of a significant medical innovation with the upcoming launch of <keyword id="23029757" type="General" weightage="20" keywordseo="PresVu-eye-drops" source="keywords">PresVu eye drops</keyword>, a groundbreaking treatment aimed at reducing dependency on <keyword id="23034012" type="General" weightage="20" keywordseo="reading-glasses" source="keywords">reading glasses</keyword>. Developed by Mumbai-based <keyword id="20007796" type="General" weightage="20" keywordseo="Entod-Pharmaceuticals" source="keywords" meta.keywordsubtype="org" meta.entityname="Entod Pharmaceuticals" meta.hostid="261" meta.entityid="Entod Pharmaceuticals">Entod Pharmaceuticals</keyword>, PresVu has recently received approval from the Drug Controller General of India (DCGI) and is scheduled to hit the market in early October 2024. <h3 style="line-height:1.2;margin-top:14pt;margin-bottom:4pt;">What is PresVu?</h3>PresVu eye drops are designed to treat <keyword id="23035383" type="General" weightage="20" keywordseo="presbyopia" source="keywords">presbyopia</keyword>, a common age-related condition that affects the eye's ability to focus on nearby objects. This condition, which typically begins in the early 40s, leads to a gradual decline in <keyword id="23035385" type="General" weightage="20" keywordseo="near-vision" source="keywords">near vision</keyword>, making reading glasses a necessity for millions. As per estimates, nearly one third of Indian adults suffer from the condition. PresVu offers a novel solution, aiming to restore visual independence to those suffering from mild to moderate presbyopia. <div type="Article" hostid="261" msid="112800837" title="Scientists want to help drug addicts recover — by giving them psychedelics" mstype="2" mssubtype="0"></div><h2>How does it work?</h2>The drug contains <keyword id="23035386" type="General" weightage="20" keywordseo="pilocarpine-hydrochloride" source="keywords">pilocarpine hydrochloride</keyword> — a plant-derived compound that has been used for decades to treat various eye conditions and dry mouth. The drops are intended for daily use, with effects lasting several hours, allowing users to perform tasks like reading without the need for glasses. As per the company, the effects of the drops will be apparent within 15 minutes, but complete benefits are only apparent after 15 days of use. The treatment has been thoroughly tested in clinical trials across India and has shown promising results in improving near vision. <div type="Article" hostid="261" msid="112738885" title="India bans 156 commonly used combination drugs citing possible risks to humans" mstype="2" mssubtype="0"></div><h2>Market impact and accessibility</h2>The introduction of PresVu is expected to make a significant impact in India, where the prevalence of presbyopia is rising. As per media sources, each vial will be priced at Rs 345, making it an affordable alternative to reading glasses. Each vial is designed to last about a month, making it a cost-effective solution for long-term use. Entod Pharmaceuticals has ambitious plans for PresVu, targeting not just the Indian market but also emerging markets in Africa and Southeast Asia. The company sees this as a step towards becoming a global innovator in ophthalmology, with future plans to out-licence products in the US market. (Editor's note: PresVu eye-drops have since been suspended by the DCGI for making exaggerated marketing claims related to the product)

Say bye-bye to reading glasses! Mumbai drug-maker to soon introduce eye drops to treat presbyopia in India

<ul class="summary-list"><li>This post originally appeared in the Insider Today newsletter.</li></ul>Happy Friday! President Joe Biden delivered a State of the Union yesterday that was unlike any in recent memory. He seized the opportunity to <a target="_blank" href="https://www.businessinsider.com/biden-state-of-the-union-speech-takeaways-trump-attacks-campaign-2024-3">tear into his predecessor</a>, Donald Trump — and Trump was quick to vent his fury online.In today's big story, we're looking at pharma companies' surging stocks and <a target="_blank" href="https://markets.businessinsider.com/news/stocks/tech-stocks-jpmorgan-retail-traders-dump-magnificent-7-for-pharma-2024-3">threatening tech darlings</a> thanks to their weight-loss drugs.What's on deck:<ul><li>Markets: Stock buybacks are <a target="_blank" href="https://markets.businessinsider.com/news/stocks/us-stock-buyback-record-forecast-cash-tech-earnings-growth-goldman-2024-3">set to make a massive comeback</a>.</li><li>Tech: Apple is having a <a target="_blank" href="https://www.businessinsider.com/apple-just-cant-seem-to-catch-a-break-this-year-2024-3">tough go of it</a>.</li><li>Business: Make way for bike lanes! <a target="_blank" href="https://www.businessinsider.com/bike-lanes-good-for-business-studies-better-streets-2024-3">They'll actually help your business</a>.</li></ul>But first, there's a new kid on the block.If this was forwarded to you, <a target="_blank" href="https://www.businessinsider.com/subscription/newsletter/insider-today">sign up here.</a><h3>The big story</h3><h2>Magnificent weight loss</h2><div type="image" title="A person holding a vial." height="650" width="1300" msid="108334141" hostid="261" sizebytes="27506"></div>Weight-loss drugs have become a trendy way to shed pounds in recent years. The companies behind them are now slimming down a new target: The Magnificent 7.Mom-and-pop investors have been net sellers of most of the Magnificent 7 stocks, selling off shares of Tesla, Apple, Alphabet, and Microsoft, according to a new note from JPMorgan.Meanwhile, pharmaceutical companies appear to <a target="_blank" href="https://markets.businessinsider.com/news/stocks/tech-stocks-jpmorgan-retail-traders-dump-magnificent-7-for-pharma-2024-3">have gained what the market's tech darlings lost</a>, writes Business Insider's Yuheng Zhan. Eli Lilly, Pfizer, and Novo Nordisk have grabbed the attention of retail investors, according to JPMorgan.That shift was evident Thursday. Shares of Novo Nordisk, the drug maker behind Wegovy, surged to a record high following an update on a new obesity drug, <a target="_blank" href="https://markets.businessinsider.com/news/stocks/novo-nordisk-stock-price-market-cap-tesla-obesity-drug-wegovy-2024-3">pushing its market cap ranking</a> past Magnificent 7 laggard Tesla.Expectations are high for fellow weight-loss drugmaker Eli Lilly. Bank of America assigned it a $1,000 price target, the highest on Wall Street, off the potential its weight-loss drug <a target="_blank" href="https://markets.businessinsider.com/news/stocks/eli-lilly-stock-outlook-weight-loss-drug-bofa-upgrade-glp1-2024-3">tops $60 billion in sales by 2030</a>. And some have speculated it could <a target="_blank" href="https://markets.businessinsider.com/news/stocks/eli-lilly-stock-diabetes-ozempic-wegovy-weight-loss-drug-pharma-2023-12">become the first trillion-dollar drug company</a>.<a target="_blank" href="https://www.businessinsider.com/magnificent-7-stocks-no-tech-bubble-burst-2024-2">Market experts expected investors to exit some of their Magnificent 7 positions</a> to realize some of the massive gains they accumulated last year. And retail investors remain buyers of Nvidia, the crown jewel of the Mag 7, JPMorgan said.But the growth these pharma companies have already shown is impressive. And it comes despite only 1% of US adults taking weight-loss drugs, <a target="_blank" href="https://www.businessinsider.com/weight-loss-stocks-supplying-developing-drugs-like-ozempic-list-2024-3">according to Bank of America</a>, which predicts that number could rise to 15% by 2035.<div type="image" title="Four photos of patients and doctors against a blue background." height="1500" width="2000" msid="108334142" hostid="261" sizebytes="156266"></div>Not unlike artificial intelligence, which has pushed tech stocks higher, the weight-loss drugs fueling pharmaceuticals' recent rally have their critics.The most notable concerns stem from a lack of understanding of the <a target="_blank" href="https://www.businessinsider.com/weight-loss-glp-1-drugs-ozempic-wegovy-mounjaro-effects-future-2023-12">long-term effects of the drugs</a>, which act on our neural pathways. For some, their loss of appetite has come with a similar apathy towards other things, like work or sex.Weight-loss drugs are also cutting more than just fat. Doctors have raised concerns about <a target="_blank" href="https://www.businessinsider.com/weight-loss-drug-semaglutide-ozempic-causes-muscle-loss-doctor-warns-2023-3">the major loss of muscle mass</a> people on these drugs can experience, especially if they're not getting enough protein or exercise.Drug companies are already considering ways to <a target="_blank" href="https://www.theatlantic.com/health/archive/2024/02/ozempics-muscle-loss-problem/677326/">incorporate drugs that can help users build muscle while also losing fat</a>, according to The Atlantic.For Wall Street, meanwhile, the equation is much simpler: Getting more people on weight-loss drugs boosts the economy. The US GDP <a target="_blank" href="https://www.businessinsider.com/us-economy-faster-growth-ozempic-glp-1-weight-loss-drugs-2024-2">could grow an extra 1% if 60 million Americans took GLP-1 drugs by 2028</a>, according to Goldman Sachs' chief economist.<h2>3 things in markets</h2><div type="image" title="Market bull money stocks" height="1537" width="2049" msid="108334235" hostid="261" sizebytes="486504"></div><ol><li>Companies buying their own stock is back in fashion. Share repurchases will hit <a target="_blank" href="https://markets.businessinsider.com/news/stocks/us-stock-buyback-record-forecast-cash-tech-earnings-growth-goldman-2024-3">$925 billion this year and $1 trillion next year</a>, according to Goldman Sachs. The trend, which will be powered by cash-rich mega-cap tech companies, is thanks to strong earnings growth, the bank said. However, the Biden administration is mulling <a target="_blank" href="https://markets.businessinsider.com/news/stocks/joe-biden-administration-wants-to-quadruple-taxes-on-stock-buybacks-2024-3">quadrupling taxes on stock buybacks</a>.</li><li>A billionaire real estate mogul has some stern words for the Fed. Barry Sternlicht said the real estate industry was "minding our own business" when <a target="_blank" href="https://www.businessinsider.com/commercial-real-estate-crisis-crash-fed-economy-inflation-rates-sternlicht-2024-3">it became "collateral damage" of the Fed's aggressive rate hikes</a>. He also pointed to the Fed's tightening policy amid government spending on the Infrastructure Investment And Jobs Act and the Inflation Reduction Act.</li><li>An old hedge-fund strategy makes a comeback. Alpha capture strategies, which generate investment portfolios by aggregating inputs from sources including human traders, market data, and sell-side research, are <a target="_blank" href="https://www.businessinsider.com/alpha-capture-hedge-funds-quantamental-2024-3">hot again in the hedge-fund world</a>.</li></ol><h2>3 things in tech</h2><div type="image" title="The Apple logo on a store." height="1334" width="2000" msid="108334237" hostid="261" sizebytes="57978"></div><ol><li>Apple can't catch a break. It's been <a target="_blank" href="https://www.businessinsider.com/apple-just-cant-seem-to-catch-a-break-this-year-2024-3">a rough week for the iPhone maker</a>: On Monday, the European Commission slapped it with a $2 billion fine. Then, a report found its iPhone sales in China had dropped 24% in the first six weeks of the year. And that's saying nothing of its abandoned EV ambitions.</li><li>Tesla's value is sagging — bringing Elon Musk down with it. The EV company has seen <a target="_blank" href="https://www.businessinsider.com/tesla-stock-price-elon-musk-mcdonalds-disney-ev-market-cap-2024-3">its value slump by $234 billion</a> this year. That's more than McDonald's, Disney, or Nike are worth. In turn, Musk's wealth has <a target="_blank" href="https://www.businessinsider.com/elon-musk-wealth-down-40-billion-this-year-tesla-stock-slide-2024-3">dropped by almost $40 billion</a> since the start of 2024.</li><li>TikTok is fighting back against Congress. Lawmakers are talking about banning the app once again — and the White House has signaled it thinks that's a good idea. TikTok has responded by <a target="_blank" href="https://www.businessinsider.com/tiktok-ban-china-congress-bill-force-sale-bytedance-why-2024-3">sending messages to some users</a> that urge them to help it stop a shutdown.</li></ol><h2>3 things in business</h2><div type="image" title="An illustration of a bike locked to a parking meter." height="1000" width="2000" msid="108334240" hostid="261" sizebytes="273882"></div><ol><li>Bike lanes are good for business. Some store owners worry that bike lanes take away parking spots, hindering customers' access to shops. But studies have shown bike lanes do nothing to reduce business — and <a target="_blank" href="https://www.businessinsider.com/bike-lanes-good-for-business-studies-better-streets-2024-3">may actually help improve sales</a>.</li><li>Temu will open to US merchants soon. US-based merchants told BI <a target="_blank" href="https://www.businessinsider.com/us-europe-amazon-sellers-eager-for-temu-platform-launch-2024-3">they're eager to sell on Temu</a> as it rapidly grows. The Chinese ecommerce platform has made a splashy entrance into the American market, reportedly <a target="_blank" href="https://www.businessinsider.com/temu-millions-on-meta-ads-staff-joked-gift-card-rewards-2024-3">spending $2 billion for advertising on Meta</a>.</li><li>Check out Rivian's new EVs. The carmaker revealed two new SUVs on Thursday: the long-awaited R2 and a surprise, smaller version called the R3. "These represent our future," Rivian CEO RJ Scaringe said. <a target="_blank" href="https://www.businessinsider.com/rivian-r2-suv-release-price-range-specs-photos-2024-3">Take a look</a> at the designs, specs, and other features.</li></ol><h2>In other news</h2><ul><li><a target="_blank" href="https://www.businessinsider.com/rupert-murdoch-marriage-engaged-elena-zhukova-2024-3">Rupert Murdoch is taking yet another shot at marriage at the age of 92</a>.</li><li><a target="_blank" href="https://www.businessinsider.com/pe-vc-investors-flock-to-sports-ai-after-peak-tv-2024-3">Private-equity and VC investors look to sports, AI, and live events as the era of peak TV draws to a close</a>.</li><li><a target="_blank" href="https://www.businessinsider.com/hedge-funds-lincoln-center-fundraiser-steve-cohen-new-york-2024-3">Inside hedge funds' big Lincoln Center bash: Caviar, acrobats, and a professed love for New York 'even if we move to Florida.'</a></li><li><a target="_blank" href="https://www.businessinsider.com/dc-restaurant-service-charges-fees-allowed-if-disclosed-to-customers-2024-3">Live in DC? Get ready for 20% service charges when you eat out</a>.</li><li><a target="_blank" href="https://www.businessinsider.com/work-life-balance-doctor-joseph-maroon-triathlete-2024-3">A busy 83-year-old doctor who does triathlons shares his 'square method' for maintaining a work-life balance</a>.</li><li><a target="_blank" href="https://markets.businessinsider.com/news/currencies/bitcoin-holdings-portfolio-allocation-price-gold-crypto-rally-safe-haven-2024-3">Bitcoin is replacing gold in investor portfolios</a>.</li><li><a target="_blank" href="https://www.businessinsider.com/netflix-love-is-blind-charlotte-suburban-housing-debate-walkable-density-2024-3?sd">'Love is Blind' fans are bashing the cookie-cutter Charlotte suburbs featured on the show. Here's how experts say they can be improved</a>.</li><li><a target="_blank" href="https://www.businessinsider.com/ray-dalio-taylor-swift-concert-selfie-endorsed-her-president-2024-3">Ray Dalio went to a Taylor Swift concert, took a selfie, and endorsed her for president</a>.</li><li><a target="_blank" href="https://www.businessinsider.com/creative-director-merkley-partners-lawsuit-sexual-assault-2024-3">Omnicom agency Merkley+Partners hit with lawsuit accusing ex-creative director of raping a social media strategist in the bathroom</a>.</li><li><a target="_blank" href="https://www.businessinsider.com/food-product-recalls-increasing-cinnamon-2024-3">Noticing more product recalls lately? It's not just you</a>.</li><li><a target="_blank" href="https://www.businessinsider.com/victoria-cruises-line-travelers-refunds-residential-cruise-vcl-2024-2">Travelers booked the residential cruise of their dreams. Now, some doubt it'll happen — and say they've waited months for refunds</a>.</li><li><a target="_blank" href="https://www.businessinsider.com/5g-advanced-standalone-6g-qualcomm-huawei-mwc-2024-3">5G had a slow and messy start. New 5G technologies could finally bring the faster networks we were promised</a>.</li></ul><h2>What's happening today</h2><ul><li>SXSW kicks off today.</li></ul>The Insider Today team: <a target="_blank" href="https://www.businessinsider.com/author/dan-defrancesco">Dan DeFrancesco</a>, deputy editor and anchor, in New York. <a target="_blank" href="https://www.businessinsider.com/author/hallam-bullock">Hallam Bullock</a>, editor, in London. <a target="_blank" href="https://www.businessinsider.com/author/jordan-parker-erb">Jordan Parker Erb</a>, editor, in New York. <a target="_blank" href="https://www.businessinsider.com/author/george-glover">George Glover</a>, reporter, in London.

Pharmaceutical companies behind weight-loss drugs are slimming down a new target: The Magnificent 7

Back in November 2022, when <keyword id="19918826" type="General" weightage="20" keywordseo="ChatGPT" source="keywords">ChatGPT</keyword> was launched for the public, interest around <keyword id="19896272" type="General" weightage="20" keywordseo="generative-AI" source="keywords">generative AI</keyword> reached new heights. The AI chatbot’s ability to respond to questions in a manner as if a human being was talking left many people surprised as well as awestruck. Soon, AI became a buzzword in the tech industry and investors started pouring funds heavily into AI companies. <h2><keyword id="19959576" type="General" weightage="100" keywordseo="Dunzo" source="keywords" meta.keywordsubtype="org" meta.entityname="Dunzo" meta.hostid="261" meta.entityid="Dunzo">Dunzo</keyword> co-founder staring his <keyword id="20128843" type="General" weightage="20" keywordseo="AI-company" source="keywords">AI company</keyword></h2>In May, an Economic Times report based on insights from market research firm Tracxn said that AI startups in India have already raised USD 91.7 million in funding so far this year, which is a significant increase from USD 29.6 million during the same period last year. And now, former <a href="https://www.businessinsider.in/business/startups/news/quick-commerce-platform-dunzo-lays-off-30-of-its-workforce/articleshow/99290084.cms" data-type="tilCustomLink" target="_blank">Dunzo </a>chief <keyword id="22628971" type="General" weightage="20" keywordseo="Mukund-Jha" source="keywords">Mukund Jha</keyword> is reportedly looking forward to start his own AI company. A Moneycontrol report citing sources said that Jha is in discussions to raise between Rs 50-80 crore (approximately $6-10 million) from <keyword id="22628972" type="General" weightage="20" keywordseo="Together-Fund" source="keywords" meta.keywordsubtype="org" meta.entityname="Together Fund" meta.hostid="261" meta.entityid="Together Fund">Together Fund</keyword> for his new venture. This comes after Jha stepped down from the board of the cash-strapped startup Dunzo last year. Jha's new venture reportedly focuses on generative <a href="https://www.businessinsider.in/business/startups/news/ai-startup-neysa-raises-20-mn-from-matrix-partners-nexus-venture-partners-more/articleshow/109181059.cms" data-type="tilCustomLink" target="_blank">artificial intelligence</a> (Gen AI) and aims to automate quality assurance (QA) processes. "Think of it as a blend of AI and SaaS," an insider told Moneycontrol. QA involves creating and running tests, identifying errors, and providing feedback to ensure products meet quality standards. <h2>What happened with Dunzo?</h2>The delivery startup Dunzo delivers essential goods like groceries, household items, fruits and vegetables, pet supplies, pharmaceuticals etc to people locally. Supported by <keyword id="19901342" type="General" weightage="20" keywordseo="Reliance-Retail" source="keywords" meta.keywordsubtype="org" meta.entityname="Reliance Retail" meta.hostid="261" meta.entityid="Reliance Retail">Reliance Retail</keyword>, the startup has faced strong competition from companies like Zepto, Swiggy, and BlinkIt. Despite raising around $500 million, Dunzo has struggled to secure additional investment and manage payroll. In February, there were rumors that Flipkart might acquire the platform, but there have been no updates on this matter since. Dunzo, on the other hand, was making headlines earlier this year for facing various financial struggles. The company’s top investor Lightbox also exited in May this year. On the other hand, the company is reportedly experiencing a cash crunch and owes approximately Rs 11.4 crore to various vendors, including Google India, Nilenso, Clover Ventures, Facebook India, Cupshup, Koo, and Glance. <h2>About Together Fund</h2>Together Fund, from which Jha is reportedly going to raise funds for his new venture, has invested in over 20 companies across various SaaS sectors, including recruitment, sales intelligence, marketing, healthcare, and cloud solutions for connected devices. “Our areas of focus span across SaaS, enterprise software, developer tools, open source software, cloud-native infrastructure and API-first businesses. We typically invest early (seed, pre A or series A) to help founders through the crucial zero-to-one part of their journey,” the company’s website reads. Together Fund was founded in 2021 by Girish Mathrubootham of Freshworks, Manav Garg of Eka Software, and Shubham Gupta formerly of Matrix Partners India. It initially raised USD 85 million for its first fund and increased the total to USD 150 million with its second fund announced in 2023

Dunzo co-founder Mukund Jha plans to start his own AI company, seeks to raise up to Rs 80 crore from Together Fund

<ul class="summary-list"><li>Ferring Pharmaceuticals, a Swiss biopharma firm, focuses on worker well-being and DEI.</li><li>Purvi Tailor, head of human resources in its US business, is on BI's <a target="_blank" class="" href="https://www.businessinsider.com/workforce-innovation-board-tackles-topics-such-as-c-suite-innovation-ai-worker-wellness-2024-8">Workforce Innovation board</a>.</li></ul>A lot of companies say they are like a family, but at Ferring Pharmaceuticals, a privately owned biopharmaceutical company headquartered in Switzerland, family-centrism is part of doing business."In the US, we are a leader in several therapeutic areas, including reproductive medicine, orthopedics, and gastroenterology," said Purvi Tailor, Ferring's head of human resources in the US. "Our mission is to help people build families and live better lives. It's a purpose that the employees that work here can feel very connected to."Tailor joined Ferring in 2021 following roles at Johnson &amp; Johnson, American Express, and JP Morgan.She said that Ferring has grown more intentional about focusing on worker well-being, which is particularly important for the highly competitive field of healthcare. "The war for talent is always on and the best talent always have options," she said.The following interview has been edited for length and clarity.What are the benefits for companies focused on worker well-being?Our overarching philosophy is that if our workers have a good sense of <a target="_blank" class="" href="https://www.businessinsider.com/flexibility-can-increase-worker-well-being-2024-8">well-being</a>, ultimately, it helps our business be that much more successful. We've defined well-being in a <a target="_blank" class="" href="https://www.businessinsider.com/employee-wellbeing-programs-help-companies-perform-better-and-manage-cost-2024-7">holistic way</a>, so it's not just about physical well-being; it's also about mental well-being and financial well-being. We've implemented various initiatives in the last two to three years that focus on each of those.You can provide a lot of tools and resources, but if you don't have the right culture within the company that people are experiencing, that obviously has a much more detrimental impact on employee experience. So, our approach is twofold. First, the benefits and the policies. And second, creating the right type of workplace that people want to be a part of.What specific programs are targeting diversity, equity, and inclusion?Relative to other companies that I've worked for, in some ways we've had the luxury to start a little bit later. Whereas some companies have been doing this for 20 years, for us it became more of a burning platform over the last couple of years.Since Covid and all the various things that have happened since, having an inclusive culture has really become one of the more important things for us.Because inclusion is something that can be very personal and difficult, we're partnering with an external event vendor to create smaller group experiences. We put a lot of things on the table and really try to make it an inclusive environment for understanding, sharing stories, and talking about different scenarios that happen in the workplace.We used scenarios that we've seen either happen at Ferring or outside, but real, lived, everyday kind of things that actually happen. Leaders found that really meaningful because it gave them an opportunity in a very safe environment to explore those situations and recognize them when they see them.The goal is to make sure that when they go back to their offices or desks, they're like, 'Okay, actually, I'm gonna be able to use that as I start to see things.'As Ferring has grown in the US, you've had to start many programs from scratch. What advice do you have for other companies that are just getting started thinking about DEI and worker well-being initiatives?What's really important is to ensure that whatever you're doing, you can connect it with the values of your company.With all of the various things that we're doing, especially in the wellness and DEI space, they align well with our values and our mission of helping people live better lives. It needs to come from an authentic place. Because it's sort of obvious when people are faking it.Our head of DEI in the US has so much passion for this space, and that really drives her as an individual and her purpose. The quality of what she puts out is remarkable, and she's able to create the right narrative that employees and leaders who are in positions to share it are able to grab some of that enthusiasm.What policies demonstrate your focus on worker well-being?One of the biggest things we've done in the last two years is a fertility benefit program called Building Families at Ferring with unlimited financial support for your journey, whether that's IVF, surrogacy, or adoption. So it covers all the many pathways that people could take to build a family.It also offers 26 weeks of paid parental leave and the policy is agnostic of your marital status and your family structures. It's truly a benefit for all that want to build a family.It's so core to our business. We thought we needed to give back to employees in the same way that we want to show up in the marketplace.What workforce issues are commonplace in the pharmaceutical industry?Attrition is systemic; it's just the norm. Over the last few years, we've managed to really stabilize the organization from an attrition perspective more so than we ever have in the previous five years.For us, retention of our talent is critical, as I know it is for all companies. You want to retain the best and make sure that they're developing and getting to whatever their aspirations are. Pharma is very competitive.We recently launched a uro-oncology business, and in the early part of this year, we hired about 60 people with roles across functions, including sales, marketing, finance, and medical. If the pharma market is generally very competitive, oncology is even more so. The things that we can do to make this a great place to work are a big part of how we approach that piece of talent management.

In the competitive world of pharma, companies need to focus on worker well-being to retain top talent, says Ferring's HR exec

<ul class="summary-list"><li>A surfer who never graduated from college has made billions in the biotech industry.</li><li>Summit Therapeutics CEO Bob Duggan is worth about $16 billion after a 1,100% stock gain in 12 months. </li></ul>A surfer <a target="_blank" class="" href="https://www.businessinsider.com/business-leaders-dont-need-college-degree-be-successful">without a college degree</a> has gone from baking cookies to building robots, minting billions in <a target="_blank" class="" href="https://www.businessinsider.com/rich-investing-longevity-biotech-vc-billionaires-2024-1">biotech</a>, and ranking among the world's richest people.Bob Duggan, 80, is the co-CEO and chairman of Summit Therapeutics, a cancer <a target="_blank" class="" href="https://www.businessinsider.com/drug-discovery-startups-set-to-take-off-top-investors-2022-11">drug developer</a>. He has tripled his net worth to $15.9 billion this year, making him the 23rd biggest wealth gainer of 2024 and the 129th richest person on the planet, per the Bloomberg Billionaires Index as of Thursday.His net worth has soared thanks to his more than 550 million shares of Summit, a roughly 75% stake. The company's stock price has surged by over 1,100% in the past 12 months, lifting its market value to over $16 billion.Summit stock jumped from about $12 on September 6 to a record high of $32 on September 13, but has retreated to around $23 since then. It spiked after the company released late-stage trial data showing one of its drugs, Ivonescimab, performed better than Merck's blockbuster Keytruda medication in some lung cancer patients.Duggan stands out in the biotech industry, where most bosses rely on their advanced degrees to navigate complex, jargon-heavy medical research.He spent six years taking classes at UC Santa Barbara in the 1960s, but never intended to get a degree as he was focused on finding ways to <a target="_blank" class="" href="https://www.businessinsider.com/how-to-earn-passive-income-strategies-build-wealth-earning-money-2023-9">make money</a>, he recently told <a target="_blank" class="" href="https://www.wsj.com/tech/biotech/how-a-surfer-who-never-finished-college-became-a-biotech-billionaire-c71eb75f">The Wall Street Journal</a>. Those included investing in Ethernet companies.Duggan opened a bakery called Cookie Muncher's Paradise in 1976 with the help of his then-brother-in-law. They converted it into a luxury sandwich chain, grew it to 16 locations, and then sold it for about $6 million in 1987, according to Bloomberg."People laugh that I was in the cookie business. But you know what? It was the bestselling chocolate-chip cookie ever," he told WSJ. "You know why? Because we engineered it. We engineered it specifically so that it would be soft, so that when you pulled it away, it was like a pizza."<div type="image" title="Summit Therapeutics CEO Bob Duggan." height="1200" width="1345" msid="113698804" hostid="261" sizebytes="51332"></div>Duggan became the CEO and chairman of Computer Motion, a <a target="_blank" class="" href="https://www.businessinsider.com/how-to-earn-passive-income-strategies-build-wealth-earning-money-2023-9">robotic surgery</a> company, in 1990. Intuitive Surgical acquired it for $67 million in stock in 2003, allowing Duggan to cash out his stake for over $150 million eventually.Spurred on by his son's death from brain cancer, Duggan started building a stake in Pharmacyclics, a maker of cancer drugs, in 2004. Pharmaceutical titan AbbVie bought the business for $21 billion in cash and stock in 2015, netting Duggan more than $3 billion, per Bloomberg.He joined Summit's board in 2019 and became CEO and chairman in 2020, making cancer drugs his principal focus. He appears to have caught lightning twice in the brutal biotech space, where many companies pour tons of money and years of work into medications that turn out to be duds.Duggan is also a megadonor to the Church of Scientology, and has backed himself to find and bet on more winning businesses as the head of his own venture capital firm, Duggan Investments.

A surfer without a degree is worth $16 billion after his biotech company's stock soared 1,100% in a year

<keyword id="146977" type="General" weightage="50" keywordseo="glenmark-pharmaceuticals-ltd" source="Orion">Glenmark Pharmaceuticals Ltd</keyword> on Tuesday said it has received final approval from the US health regulator for its generic Fluphenazine Hydrochloride tablets used to treat certain types of mental disorders. The approval granted by the US Food &amp; Drug Administration (US FDA) is for Fluphenazine Hydrochloride tablets of strengths 1 mg, 2.5 mg, 5 mg and 10 mg, Glenmark said in a statement. These are the generic versions of Prolixin tablets in same strengths of Apothecon Inc, it added. The company's Fluphenazine Hydrochloride tablets will be distributed in the US by Glenmark Pharmaceuticals Inc, USA, it said. For the 12 months ended September 2023, Prolixin tablets in the same strengths achieved annual sales of approximately USD 18.1 million, Glenmark said citing IQVIA data. (This copy will be updated)

Glenmark gets USFDA nod for generic drug used to treat mental disorder

<ul><li>All the four brands have a combined market size of ₹1800 crore and accounted for as much as ₹33 crore in revenues in FY22.</li><li>The pharma company will take over the manufacturing, marketing and distribution of these brands in India.</li><li>The integration and transition of the brands are expected to be completed in the next two weeks.</li></ul>KKR-backed <keyword id="505502" type="General" weightage="80" keywordseo="jb-chemicals-and-pharmaceuticals" source="Orion">JB Chemicals and Pharmaceuticals</keyword> said that it acquired four pediatric brands — Z&amp;D, Pedicloryl, Pecef and Ezinapi from <keyword id="177825" type="General" weightage="20" keywordseo="Dr-Reddys-Laboratories" source="Orion">Dr Reddy’s Laboratories</keyword>. The acquisition has been done for a cash consideration of ₹98.3 crore, excluding working capital and taxes. All the four brands have a combined market size of ₹1800 crore and accounted for as much as ₹33 crore in revenues in FY22. “Overall, the brands acquired have significant growth potential to strengthen our already established presence in the pediatric category, which is synergistic to our current portfolio, speciality depth and geographical presence,” said <keyword id="1217" type="General" weightage="80" keywordseo="nikhil-chopra" source="Orion">Nikhil Chopra</keyword>, CEO at <keyword id="5340080" type="General" weightage="20" keywordseo="JB-Pharma" source="Orion">JB Pharma</keyword>. Z&amp;D produces zinc supplements used for boosting immunity. Pedicloryl oral solution is used in children in hospitals for idiopathic pain management. Pecef caters to the bacterial infections as well as respiratory tract infections in children. Ezinapi cream is used as an emollient for diaper rashes in infants. JB Pharma will take over the manufacturing, marketing and distribution of these brands in India. “It will also help us significantly leverage our on-the-ground field force strength and widen our offerings in the pediatric basket - comprising gut health and respiratory infection products for healthcare professionals across the country,” said Chopra. The integration and transition of the brands are expected to be completed in the next two weeks. “All the four brands have a lion’s share in their respective spaces. We will continue to focus on evaluating opportunities for strengthening our India domestic business,” Chopra added. According to media <a href="https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/jb-pharma-acquires-paediatric-brands-from-dr-reddys-for-rs-98-3-crore/articleshow/92590368.cms">reports</a>, the pharma company has been looking out for companies to acquire in the domestic market. It had also acquired brands from Sanzyme — which deals in probiotics and reproductive health for ₹628 crore in January. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/corporates/news/ambani-and-adani-valuations-surge-while-tatas-birlas-see-major-declines-in-the-first-half-of-2022/articleshow/92593235.cms">Ambani and Adani valuations surge while Tatas, Birlas see major declines in the first half of 2022</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/telecom/news/telecom-gear-firm-parallel-wireless-lays-off-500-employees-including-in-india/articleshow/92592940.cms">Telecom gear firm Parallel Wireless lays off 500 employees including in India</a>

You Searched For "pharmaceutical company" and got 11 results

Human ageing dramatically speeds up around ages 44 and 60, claims study

BI India Bureau

PresVu eye drops: Why has a pharma company fallen in controversy for claiming to cure near-sightedness?

BI India Bureau

Say bye-bye to reading glasses! Mumbai drug-maker to soon introduce eye drops to treat presbyopia in India

BI India Bureau

Pharmaceutical companies behind weight-loss drugs are slimming down a new target: The Magnificent 7

Dan DeFrancesco

Dunzo co-founder Mukund Jha plans to start his own AI company, seeks to raise up to Rs 80 crore from Together Fund

Divyanshi Sharma

In the competitive world of pharma, companies need to focus on worker well-being to retain top talent, says Ferring's HR exec

Julia Hood

A surfer without a degree is worth $16 billion after his biotech company's stock soared 1,100% in a year

Theron Mohamed

Glenmark gets USFDA nod for generic drug used to treat mental disorder

PTI

JB Pharma acquires four pediatric brands of Dr Reddy’s Labs for ₹98.3 crore

Vaamanaa Sethi

I used Mark Cuban's new pharmacy company to order my medicine, and the prescription was a little cheaper. Here's how it worked.

Allana Akhtar

Inside a prison healthcare company's ownership shell game

Dakin Campbell,Nicole Einbind…

Popular Keywords

Buying Guides